The Latest Breaking News from TGTX

A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry’s bright outlook, biotech stocks MannKind (MNKD), Illumina (ILMN), and TG Therapeutics (TGTX) could be ideal watchlist additions for potential growth. Read…

The need for innovative healthcare solutions, personalized medicines and treatments, and the use of advanced technologies will propel the biotech industry forward. Amid this backdrop, let’s explore the investment potential of biotech stocks TG Therapeutics (TGTX), Galapagos (GLPG), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR).

TG Therapeutics Inc's (NASDAQ:TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) HC Wainwright has slashed the price target from $68 to $19, with the Buy rating unchanged.…

The FDA has extended the review period of TG Therapeutics Inc's (NASDAQ:TGTX) biologics license application and supplemental New Drug Application for ublituximab in combination with Ukoniq (umbralisib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The Prescription Drug User Fee Act (PDUFA) goal date is postponed to June 25. The FDA notified…